Literature DB >> 2649653

Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein.

K Kozarsky1, M Penman, L Basiripour, W Haseltine, J Sodroski, M Krieger.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) envelope protein is synthesized as a gp160 precursor that is cleaved to a 120 kDa exterior glycoprotein (gp120) and a 41 kDa transmembrane glycoprotein (gp41). The HIV-1 envelope protein was stably expressed under the control of the transactivator proteins tat and rev, in wild-type and mutant Chinese hamster ovary (CHO) cells. The mutant, ldlD, is conditionally defective for the addition of galactose and N-acetylgalactosamine to oligosaccharide chains. The effects of glycosylation modification on the HIV-1 envelope's structure and function were examined. The effects of galactosylation on the structure of the envelope proteins suggest that cleavage of the gp160 precursor into gp120 and gp41 occurs intracellularly, apparently concurrent with the addition of galactose to N-linked oligosaccharides of the envelope proteins. No evidence for O-linked glycosylation of the envelope proteins in CHO cells was observed. The envelope protein in the transfected hamster cells mediated the fusion of these cells with CD4-positive lymphocytes, and this fusogenic activity was independent of the addition of either galactose or N-acetylgalactosamine to oligosaccharides in the transfected cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649653

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  27 in total

1.  Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity.

Authors:  C Yang; R W Compans
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*).

Authors:  V A Morozov; A V Morozov; S Lagaye
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

3.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.

Authors:  D C Chan; C T Chutkowski; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Inhibiting HIV fusion with a beta-peptide foldamer.

Authors:  Olen M Stephens; Sunghwan Kim; Brett D Welch; Michael E Hodsdon; Michael S Kay; Alanna Schepartz
Journal:  J Am Chem Soc       Date:  2005-09-28       Impact factor: 15.419

5.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 6.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

7.  Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.

Authors:  P Simmonds; L Q Zhang; F McOmish; P Balfe; C A Ludlam; A J Brown
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus.

Authors:  J E Hansen; H Clausen; S L Hu; J O Nielsen; S Olofsson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

Authors:  E Fenouillet; J C Gluckman; E Bahraoui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

10.  Mutations in the cytoplasmic tail of murine leukemia virus envelope protein suppress fusion inhibition by R peptide.

Authors:  M Li; C Yang; R W Compans
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.